mTOR Inhibition Impairs the Activation and Function of Belatacept-Resistant CD4<sup>+</sup>CD57<sup>+</sup> T Cells In Vivo and In Vitro

mTOR Inhibition Impairs the Activation and Function of Belatacept-Resistant CD4<sup>+</sup>CD57<sup>+</sup> T Cells In Vivo and In Vitro

Calcineurin inhibitors have improved graft survival in solid-organ transplantation but their use is limited by toxicity, requiring a switch to another immunosuppressor in some cases. Belatacept is one option that has been shown to improve graft and patient survival despite being associated with a hi...

Full description

Bibliographic Details
Main Authors: Florence Herr, Manon Dekeyser, Jerome Le Pavec, Christophe Desterke, Andrada-Silvana Chiron, Karen Bargiel, Olaf Mercier, Amelia Vernochet, Elie Fadel, Antoine Durrbach
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Pharmaceutics
Subjects:
solid-organ transplantation
checkpoint inhibitors
mTOR inhibitors
belatacept-resistant T cells
Online Access:https://www.mdpi.com/1999-4923/15/4/1299

Internet

https://www.mdpi.com/1999-4923/15/4/1299

Similar Items